Determination of Olanzapine and N-desmethyl-olanzapine in Plasma Using a Reversed-Phase HPLC Coupled with Coulochemical Detection: Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Metabolic Parameters

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Lu, Mong Liang ^a,b   Lin, Chia Hui ^c   Chen, Yi Chuan ^c   Yang, Huai Chih ^c   Wu, Tzu Hua ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; GLUCOSE; INSULIN; NOROLANZAPINE; OLANZAPINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; COULOMETRY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIMIT OF QUANTITATION; MALE; RELIABILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84878574398     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065719     Document Type: Article

References (50)

1. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, et al. (1999) Olanzapine: a basic science update. Br J Psychiatry Suppl: 36-40.
2. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, et al. (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14: 111-123.
3. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. (2010) Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006654.
4. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM, (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37: 177-193.
5. Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F, (2002) Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24: 518-526.
6. Wu TH, Chiu CC, Shen WW, Lin FW, Wang LH, et al. (2008) Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiatry 32: 1889-1893.
7. Haslemo T, Eikeseth PH, Tanum L, Molden E, Refsum H, (2006) The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 62: 1049-1053.
8. Melkersson KI, Hulting AL, Brismar KE, (2000) Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61: 742-749.
9. Theisen FM, Haberhausen M, Schulz E, Fleischhaker C, Clement HW, et al. (2006) Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 28: 750-759.
10. Muench J, Hamer AM, (2010) Adverse effects of antipsychotic medications. Am Fam Physician 81: 617-622.
11. Newcomer JW, (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68Suppl 4: 8-13.
12. Haddad PM, Sharma SG, (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911-936.
13. Simon V, van Winkel R, De Hert M, (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70: 1041-1050.
14. Melkersson KI, Dahl ML, (2003) Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl) 170: 157-166.
15. Vuksan-Cusa B, Jakovljevic M, Sagud M, Mihaljevic Peles A, Marcinko D, et al. (2011) Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 189: 21-25.
16. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, et al. (2007) A new brief instrument for assessing decisional capacity for clinical research. Archives of general psychiatry 64: 966-974.
17. Bogusz MJ, Kruger KD, Maier RD, Erkwoh R, Tuchtenhagen F, (1999) Monitoring of olanzapine in serum by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 732: 257-269.
18. Chin C, Zhang ZP, Karnes HT, (2004) A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine. J Pharm Biomed Anal 35: 1149-1167.
19. Josefsson M, Roman M, Skogh E, Dahl ML, (2010) Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. J Pharm Biomed Anal 53: 576-582.
20. Raggi MA, Casamenti G, Mandrioli R, Volterra V, (2001) A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. Journal of Chromatography B: Biomedical Sciences and Applications 750: 137-146.
21. Raggi MA, Mandrioli R, Sabbioni C, Ghedini N, Fanali S, et al. (2001) Determination of Olanzapine and Desmethylolanzapine in the Plasma of Schizophrenic Patients by Means of an Improved HPLC Method with Amperometric Detection. Chromatographia 54: 203-207.
22. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, et al. (1995) Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 668: 85-90.
23. Saracino MA, Koukopoulos A, Sani G, Amore M, Raggi MA, (2007) Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients. Ther Drug Monit 29: 773-780.
24. Saracino MA, Gandolfi O, Dall'Olio R, Albers L, Kenndler E, et al. (2006) Determination of Olanzapine in rat brain using liquid chromatography with coulometric detection and a rapid solid-phase extraction procedure. Journal of Chromatographic Science 1122: 21-27.
25. Sabbioni C, Saracino MA, Mandrioli R, Albers L, Boncompagni G, (2004) Rapid analysis of olanzapine and desmethylolanzapine in human plasma using high-performance liquid chromatography with coulometric detection. Analytica chimica acta 516: 111-117.
26. Chiu JA, Franklin RB, (1996) Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis 14: 609-615.
27. Bergemann N, Frick A, Parzer P, Kopitz J, (2004) Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 37: 63-68.
28. D'Arrigo C, Migliardi G, Santoro V, Spina E, (2006) Determination of olanzapine in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Therapeutic Drug Monitoring 28: 388-393.
29. Guidance for Industry. Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug administration. Available: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. Accessed 2013 May 4.
30. Benjamini Y, Yekutieli D, (2001) The control of the false discovery rate in multiple testing under dependency. Ann Stat 29: 1165-1188.
31. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, et al. (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37: 243-265.
32. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, et al. (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44: 195-235.
33. Schwenger E, Dumontet J, Ensom MH, (2011) Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet 50: 415-428.
34. Citrome L, Holt RI, Walker DJ, Hoffmann VP, (2011) Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig 31: 455-482.
35. Elman I, Borsook D, Lukas SE, (2006) Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 31: 2091-2120.
36. Chiu CC, Chen KP, Liu HC, Lu ML, (2006) The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 26: 504-507.
37. Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML, (2010) The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 34: 866-870.
38. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, et al. (2006) The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 136: 1731S-1740S.
39. Levine J, Sela BA, Osher Y, Belmaker RH, (2005) High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 29: 1181-1191.
40. Virgos C, Martorell L, Simo JM, Valero J, Figuera L, et al. (1999) Plasma homocysteine and the methylenetetrahydrofolate reductase C677T gene variant: lack of association with schizophrenia. Neuroreport 10: 2035-2038.
41. Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, et al. (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159: 1790-1792.
42. Susser E, Brown AS, Klonowski E, Allen RH, Lindenbaum J, (1998) Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 44: 141-143.
43. Lee YS, Han DH, Jeon CM, Lyoo IK, Na C, et al. (2006) Serum homocysteine, folate level and methylenetetrahydrofolate reductase 677, 1298 gene polymorphism in Korean schizophrenic patients. Neuroreport 17: 743-746.
44. Kim TH, Moon SW, (2011) Serum homocysteine and folate levels in korean schizophrenic patients. Psychiatry Investig 8: 134-140.
45. Reif A, Pfuhlmann B, Lesch KP, (2005) Homocysteinemia as well as methylenetetrahydrofolate reductase polymorphism are associated with affective psychoses. Prog Neuropsychopharmacol Biol Psychiatry 29: 1162-1168.
46. Dicker-Brown A, Fonseca VA, Fink LM, Kern PA, (2001) The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. Atherosclerosis 158: 297-301.
47. Henderson DC, Copeland PM, Nguyen DD, Borba CP, Cather C, et al. (2006) Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta Psychiatr Scand 113: 121-125.
48. Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, et al. (2010) Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients. European journal of clinical pharmacology 66: 465-474.
49. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, et al. (2008) The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Therapeutic drug monitoring 30: 35-40.
50. Laika B, Leucht S, Heres S, Schneider H, Steimer W, (2010) Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. The pharmacogenomics journal 10: 20-29.